These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35747566)

  • 21. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients.
    Hu Y; Wang M; Chen Y; Chen X; Fang F; Liu S; Zhang Y; Wu X; Zhu P
    Chin Med J (Engl); 2014; 127(15):2765-70. PubMed ID: 25146610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
    Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
    Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blast size-specific flowcytometric ploidy assessment using FxCycle
    Bommannan K; Arumugam JR; Koshy T; Radhakrishnan V; Sagar TG; Sundersingh S
    Int J Lab Hematol; 2021 Aug; 43(4):760-770. PubMed ID: 33345449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach.
    Rai S; Das N; Gupta R; Kumar L; Sharma A; Singh S; Prajapati VK
    Int J Lab Hematol; 2023 Apr; 45(2):179-186. PubMed ID: 36403963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
    Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
    Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
    Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunophenotype characteristics of patients with multiple myeloma in different risk stratification].
    Hu K; Wang J; Zhu MX; Wang YF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1624-7. PubMed ID: 25543486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
    Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
    Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow Cytometric DNA Ploidy Analysis in Haemato-Lymphoid Neoplasms: An Analysis of 132 Cases.
    Gupta N; Mittal A; Dadu T; Choudhary D; Handoo A
    Int J Hematol Oncol Stem Cell Res; 2022 Jan; 16(1):34-46. PubMed ID: 35975117
    [No Abstract]   [Full Text] [Related]  

  • 32. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
    Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
    Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
    Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
    Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
    García-Sanz R; Orfão A; González M; Tabernero MD; Bladé J; Moro MJ; Fernández-Calvo J; Sanz MA; Pérez-Simón JA; Rasillo A; Miguel JF
    Blood; 1999 Feb; 93(3):1032-7. PubMed ID: 9920853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.
    Salem DA; Scott D; McCoy CS; Liewehr DJ; Venzon DJ; Arons E; Kreitman RJ; Stetler-Stevenson M; Yuan CM
    Cytometry B Clin Cytom; 2019 Jul; 96(4):275-282. PubMed ID: 31077558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of Bone Marrow Flow Cytometry Analysis in Patients With Plasma Cell Neoplasm in Thailand: A Single Institutional Study.
    Limvorapitak W; Srisum-Ang T; Chimres C; Warnnissorn N; Kanitsap N
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e27-37. PubMed ID: 26796980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Almeida J; Orfao A; Mateo G; Ocqueteau M; García-Sanz R; Moro MJ; Hernandez J; Ortega F; Borrego D; Barez A; Mejido M; San Miguel JF
    Pathol Biol (Paris); 1999 Feb; 47(2):119-27. PubMed ID: 10192879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunophenotype of normal and myelomatous plasma-cell subsets.
    Robillard N; Wuillème S; Moreau P; Béné MC
    Front Immunol; 2014; 5():137. PubMed ID: 24744760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
    Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.